IFP Advisors Inc Has $2.04 Million Stake in Becton, Dickinson and Company $BDX

IFP Advisors Inc grew its position in Becton, Dickinson and Company (NYSE:BDX) by 71.5% during the 4th quarter, Holdings Channel.com reports. The firm owned 10,488 shares of the medical instruments supplier’s stock after purchasing an additional 4,371 shares during the period. IFP Advisors Inc’s holdings in Becton, Dickinson and Company were worth $2,035,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Poehling Capital Management INC. grew its position in shares of Becton, Dickinson and Company by 2.1% in the fourth quarter. Poehling Capital Management INC. now owns 8,255 shares of the medical instruments supplier’s stock valued at $1,602,000 after purchasing an additional 173 shares during the last quarter. Cullen Frost Bankers Inc. grew its position in shares of Becton, Dickinson and Company by 3.5% in the fourth quarter. Cullen Frost Bankers Inc. now owns 3,268 shares of the medical instruments supplier’s stock valued at $634,000 after purchasing an additional 112 shares during the last quarter. Creative Financial Designs Inc. ADV grew its position in shares of Becton, Dickinson and Company by 147.8% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 840 shares of the medical instruments supplier’s stock valued at $163,000 after purchasing an additional 501 shares during the last quarter. Tredje AP fonden grew its position in shares of Becton, Dickinson and Company by 7.4% in the fourth quarter. Tredje AP fonden now owns 291,720 shares of the medical instruments supplier’s stock valued at $56,614,000 after purchasing an additional 20,000 shares during the last quarter. Finally, Larson Financial Group LLC grew its position in shares of Becton, Dickinson and Company by 1.7% in the fourth quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock valued at $627,000 after purchasing an additional 53 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Stifel Nicolaus decreased their target price on Becton, Dickinson and Company from $215.00 to $175.00 in a research report on Thursday, May 7th. Argus cut their price target on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a research note on Monday, March 23rd. Royal Bank Of Canada set a $175.00 price target on Becton, Dickinson and Company in a research note on Tuesday, April 14th. Barclays boosted their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Finally, Evercore boosted their price target on Becton, Dickinson and Company from $180.00 to $190.00 in a research note on Thursday, May 7th. Seven analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $184.86.

Becton, Dickinson and Company Stock Up 1.0%

NYSE BDX opened at $147.76 on Friday. The business has a fifty day moving average price of $152.83 and a two-hundred day moving average price of $178.07. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The stock has a market capitalization of $40.71 billion, a PE ratio of 37.41, a PEG ratio of 10.35 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. During the same period in the prior year, the company earned $3.35 earnings per share. The company’s quarterly revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities analysts expect that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has approved a share buyback plan on Tuesday, January 27th that permits the company to repurchase $10.00 million in shares. This repurchase authorization permits the medical instruments supplier to purchase up to 0% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 106.33%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.